Skip to main content
. 2021 May 10;9(11):e003134. doi: 10.1136/jitc-2021-003134

Figure 6.

Figure 6

CD155 expression is related to resistance to ICIs in patients with melanoma with inflamed tumor microenvironment, including acquired resistance. (A) Survival curves of patients with melanoma. We analyzed a prognosis in 144 patients with melanoma who received ICIs. PFS and OS were defined as the time from the initiation of first ICIs until the first observation of disease progression or death from any cause and the time from the initiation of first ICIs until death from any cause, respectively. Survival curves according to CD8+ T-cell infiltration and CD155 expression are shown. (B and C) CD155 staining in MEL04 and CD155 expression change from baseline to resistance state. We stained paired formalin-fixed, paraffin-embedded samples at both baseline (before ICI) and resistance state (after ICI) in 25 patients with melanoma who received ICIs, and evaluated their staining as scores (0, 1+, 2+, and 3+). In addition to all 25 patients, the CD155 expression change was also analyzed according to CD8+ T-cell infiltration at resistance state. CD155 staining in MEL04 (B) and the summary of changes (C) are shown. Survival curves were analyzed using the Kaplan-Meier method and compared among groups using the log-rank test in (A), and paired t-tests were used in (C) for statistical analyses. *, p<0.05; **, p<0.01; ***, p<0.001; ****, p<0.0001; ICIs, immune checkpoint inhibitors; ns, not significant; OS, overall survival; PFS, progression-free survival.